This document discusses the diagnosis and treatment of coronary artery disease in patients with type 2 diabetes mellitus. It finds that cardiovascular disease is a major cause of mortality for those with diabetes. The document classifies coronary artery disease, discusses clinical manifestations such as stable angina and acute coronary syndrome, and recommends both non-pharmacological and pharmacological therapy including lifestyle changes, renin-angiotensin system inhibitors, and calcium channel blockers. It concludes that appropriate screening and management is crucial given the rise in diabetes and associated cardiovascular risks.
This document discusses the diagnosis and treatment of coronary artery disease in patients with type 2 diabetes mellitus. It finds that cardiovascular disease is a major cause of mortality for those with diabetes. The document classifies coronary artery disease, discusses clinical manifestations such as stable angina and acute coronary syndrome, and recommends both non-pharmacological and pharmacological therapy including lifestyle changes, renin-angiotensin system inhibitors, and calcium channel blockers. It concludes that appropriate screening and management is crucial given the rise in diabetes and associated cardiovascular risks.
This document discusses the diagnosis and treatment of coronary artery disease in patients with type 2 diabetes mellitus. It finds that cardiovascular disease is a major cause of mortality for those with diabetes. The document classifies coronary artery disease, discusses clinical manifestations such as stable angina and acute coronary syndrome, and recommends both non-pharmacological and pharmacological therapy including lifestyle changes, renin-angiotensin system inhibitors, and calcium channel blockers. It concludes that appropriate screening and management is crucial given the rise in diabetes and associated cardiovascular risks.
This document discusses the diagnosis and treatment of coronary artery disease in patients with type 2 diabetes mellitus. It finds that cardiovascular disease is a major cause of mortality for those with diabetes. The document classifies coronary artery disease, discusses clinical manifestations such as stable angina and acute coronary syndrome, and recommends both non-pharmacological and pharmacological therapy including lifestyle changes, renin-angiotensin system inhibitors, and calcium channel blockers. It concludes that appropriate screening and management is crucial given the rise in diabetes and associated cardiovascular risks.
Download as PPTX, PDF, TXT or read online from Scribd
Download as pptx, pdf, or txt
You are on page 1of 12
Pembimbing:
DIAGNOSIS AND dr. Arif Gunawan, Sp.PD, MARS
THERAPY OF Soraya Olyfia ARTERY CORONARY 030.10.258 DISEASE IN TYPE 2 Sri gusfita 030.11.278 DIABETES Made Ayu Laksmie R. MELLITUS 030.12.152 INTRODUCTION
Cardiovascular disease (CVD) is the major cause of morbidity
and mortality for individuals with diabetes and is the largest contributor to the direct and indirect costs of diabetes. The common conditions coexisting with type 2 diabetes (hypertension and dyslipidemia) are clear risk factors for CVD, and diabetes itself confers independent risk. Prevalence of Cardiac Disease among Diabetics Diabetes mellitus has been well described as a cardiovascular risk factor in developed countries. In the Framingham study,the incidence of cardiovascular disease among diabetic men was twice that among nondiabetic men, and similarly was three times more elevated in diabetic women compared to nondiabetic women In a recent metaanalysis by Berry et al. reviewing the lifetime risks of cardiovascular disease, 18 studies involving 257,384 men and women were reviewed. Patients were stratified by blood pressure, cholesterol level, smoking status, and diabetes status and by age group as well as gender and race Prevalence of Cardiac Disease among Diabetics Furthermorethe differential impact of diabetes on coronary artery disease mortality in men and women has been the subject of multiple studies; Lee et al. reported the relative risk of coronary heartdisease mortality to be 2.5 in women, compared to 1.85 in men CLASSIFICATION 1. Stable angina pectoris 2. Acute coronery syndrome - Unstable angina pectoris - Myocardial infarction without ST segment elevation (NSTEMI) - Myocardial infarction with ST segment elevation (NSTEMI) CLINICAL MANIFESTASION 1. Stable angina pectoris - Quality dull pain, like : * Taste crushed / weight in chest * Pain radiating to the left arm, neck, shoulder and chin * Chest pain <20 minutes 2. Acute coronery syndrome Suddenly at rest, sleep, symptoms occur much longer than stable angina pectoris, rest or medications usually can not relieve symptoms CLINICAL MANIFESTASION a. Unstable angina pectoris without an increase in cardiac marker enzyme (CK-MB, troponin) with or without ECG changes indicate ischemia (ST segment depression, T wave inversion and ST segment elevation transients).
b. Myocardial infarction without ST segment elevation (NSTEMI)
Ischemia occurring severe enough to lead to myocardial damage characterized by an increase in markers of cardiac enzyme (CK-MB, troponin).
c. Myocardial infarction with ST segment elevation (NSTEMI)
This type is more dangerous and a state of emergency, this type can be known through the EKG shows changes called ST segment elevation. ST segment elevation is an indication of damage to the heart muscle which is quite large (occurring due to total occlusion of the coronary arteries). DIAGNOSIS
Blood pressure measurement should bedone by a trained
individual and follow the guidelines established for the general population
Blood pressure should be measured at every routine visit.
Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. THERAPY NON Pharmacological
- The DASH study evaluated the impact of healthy dietary patterns in
individuals without diabetes and has shown antihypertensive effects similar to those of pharmacological monotherapy. - Lifestyle therapy consists of restricting sodium intake, reducing excess body weight, increasing consumption of fruits, vegetables, and low-fat dairy products, avoiding excessive alcohol consumption (no more than 2 servings per day in men and no more than 1 serving per day in women)(13);and increasing activitylevels. - Nonpharmacological therapy is reasonable in individuals with diabetes and mildly elevated blood pressure (SBP .120 mmHg or DBP .80 mmHg). If the blood pressure is conrmed to be 140mmHg systolic and/or 90 mmHg diastolic, pharmacological therapy should be initiated along with nonpharmacological therapy THERAPY Pharmacological
In people with diabetes, inhibitors of the renin-angiotensin system
(RAS) may have unique advantages for initial or early treatment of hypertension.
In patients with congestive heart failure (CHF), including subgroups
with diabetes, ARBs have been shown to reduce major CVD outcome. In type 2 diabetic patients with signicant diabetic kidney disease, ARBs were superior to calcium channel blockers for reducingheartfailur In type 2 diabetic patients with signicant diabetic kidney disease, ARBs were superior to calcium channel blockers for reducing heart failure CONCLUSION
Diabetes mellitus is associated with an increased risk of
cardiovascular death and a higher incidence of cardiovascular diseases including coronary artery disease. The substantial rise in prevalence of diabetes will ultimately lead to a huge increase in the demand for primary, secondary, and tertiary healthcare services globally. The need for appropriate screening and cardiac testing is crucial to help better manage the end result (cardiovascular disease) of this global epidemic. REFERENCE
1. Wong P, Fuller PJ, Gillespie MT, Milat F. Bone Disease in
Thalassemia: A Molecular and Clinical Overview. Endocr Rev; 10(1210): 2015-1105 2. Sabath DE, Harvey A. A Multiplex Approach to the Molecular Diagnosis of -Thalassemia 3. Vanichsetakul, Preeda. Thalassemia: Detection, Management,Prevention & curative treatment. The Bangkok Medical Journal:2011